Patents by Inventor Maxence BOS

Maxence BOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20250042897
    Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
    Type: Application
    Filed: November 9, 2022
    Publication date: February 6, 2025
    Applicant: Vigil Neuroscience, Inc.
    Inventors: Jonathan B. HOUZE, Bhaumik PANDYA, Alan P. KAPLAN, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20240309003
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: May 4, 2022
    Publication date: September 19, 2024
    Applicant: Vigil Neuroscience, Inc.
    Inventors: Jonathan B. HOUZE, Maxence BOS, John MANCUSO, Ivan FRANZONI, Bhaumik PANDYA, Alan KAPLAN
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20240182477
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: September 21, 2023
    Publication date: June 6, 2024
    Inventors: Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20230295169
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: November 30, 2022
    Publication date: September 21, 2023
    Inventors: Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS
    Publication number: 20230295152
    Abstract: The present disclosure relates to compounds of formula (Ia) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling. These compounds may also be useful in treating cancer when administered in combination with at least one additional therapy.
    Type: Application
    Filed: November 20, 2020
    Publication date: September 21, 2023
    Applicant: SENDA BIOSCIENCES, INC.
    Inventors: Alessandra BARTOLOZZI, John Robert PROUDFOOT, Timothy BRIGGS, John MANCUSO, Karunakar Reddy BONEPALLY, Patrick BUREAU, Tianlin GUO, Maxence BOS, Anna BLOIS, Bernard LANTER, Steven John TAYLOR, Leonard BUCKBINDER, Francesca BARONE
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20230002390
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: May 4, 2021
    Publication date: January 5, 2023
    Inventors: Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI